International News
European Hematology Association (EHA) Meeting
With approximately 10,000 hematology professionals from around the globe in attendance, t he 23rd Annual EHA meeting took place in Stockholm, Sweden from June 14 – 17. The program focussed on state-of-the-art clinical practice, providing an invaluable educational opportunity to review and discuss the latest findings in hematology research.
Dr. Donna Reece, from the Princess Margaret Cancer Centre of Toronto and Chief Medical Officer for the Myeloma Canada Research Network (MCRN), was interviewed on CAR T-Cell Therapy for patients with relapsed/refractory multiple myeloma. To view this video, click on the image above.
Interested in Learning About the Latest Myeloma Research Presented at EHA?
Register for our Educational Webinar on the Latest Myeloma Research Updates from the EHA 2018 Meeting

Presenters :

Irwindeep Sandhu, MD
Hematologist/Oncologist
Cross Cancer Institute
Associate Professor
University of Alberta
Edmonton, AB

Julie Stakiw, MD
Hematologist/Oncologist
Saskatoon Cancer Centre
Provincial Leader, Hematology
Saskatchewan Cancer Agency
Clinical Associate Professor
University of Saskatchewan
Saskatoon, SK
Join us online from the comfort of your own home! All you need is a computer, tablet or smart phone and an internet connection.

Tuesday, July 31, 2018
7:00 pm ET
International Myeloma Working Group (IMWG) Meeting
The IMWG consists of nearly 200 leading myeloma researchers from around the globe, including Canadian representatives Dre. Suzanne Trudel from Toronto, Dr. Chaim Shustik from Montreal, Dr. Nizar Bahlis from Calgary, Martine Elias and Gabriele Colasurdo from Myeloma Canada. They collaborate on a broad range of myeloma research projects. Their work focuses on clinical trials to provide a more durable remission for myeloma patients while improving quality of life and addressing the needs of both myeloma patients and the physicians who treat them.

This year’s 9 th Annual Summit IMWG took place in June 11–13 in Stockholm, Sweden. Important topics such as value-based pricing as a way to improve drug access,the use of minimal residual disease (MRD) as a clinical decision-making tool, CAR T-cell immunotherapy and BCMA clinical trial data and results were discussed.
Global Myeloma Action Network Summit
In 2013, the International Myeloma Foundation led the development of the Global Myeloma Alliance, which became the Global Myeloma Action Network (GMAN) in 2014. GMAN is comprised of a myeloma patient organizations from a number of countries in Europe, the Americas and Asia Pacific. The goal of this network is to strengthen the collective advocacy strategy for the benefit of myeloma patients across the world. While each member organization executes its own mission and vision, GMAN aims to convene members and partners to share best practices, address mutual areas of concern and elevate awareness for multiple myeloma.

At this year’s summit, the Executive Director of Myeloma Canada, Martine Elias, was invited to present a new concept for building an Advocacy University program for our global community, which included the objectives, what the program would cover, as well as and required competencies.
Martine Elias, Executive Director of Myeloma Canada
The Susie Durie Novis
Educational Grant Award
Martine Elias, Executive Director of Myeloma Canada (right), accepting the award on behalf of Myeloma Canada
by Susie Novis Durie, Founder and President of the
International Myeloma Foundation
The Susie Novis Durie Educational Grant, created to help member organizations of the IMF’s Global Myeloma Action Network (GMAN) increase education, awareness, and access to treatment, was awarded to Myeloma Canada to support the Myeloma Advocacy Program (MAP) campaign. The campaign is a unique communication vehicle that is designed to empower the community to advocate and collaborate on important topics and initiatives including drug access, drug policy and disease awareness. To learn more about Myeloma Canada’s MAP program, click here .